Tanja Mesti

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Replacement Therapy

Metastatic Colorectal Cancer

Ejection Fraction

Immune Response

Top Venues

Diagnostics (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Peter Kopač, Ana Koren, Urska Bidovec-Stojkovic, Kosnik Mitja, Luka Dejanović, Tanja Mesti, Primoz Strojan, Peter Korošec, Janja Ocvirk
Basophil Activation Test Predicts Cetuximab Anaphylaxis Severity in Alpha-Gal IgE-Positive Patients. Diagnostics (Basel, Switzerland) 14 (13) (2024)
Peter Kopač, Ana Koren, Urska Bidovec-Stojkovic, Kosnik Mitja, Luka Dejanović, Tanja Mesti, Primoz Strojan, Peter Korošec, Janja Ocvirk
Basophil Activation Test Predicts Cetuximab Anaphylaxis Severity in Alpha-Gal IgE-Positive Patients. Diagnostics (Basel, Switzerland) 14 (13) (2024)
Tanja Mesti, Cvetka Grašič Kuhar, Janja Ocvirk
Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors. Biomedicines 11 (3) (2023)
Ana Erman, Marija Ignjatović, Katja Leskovšek, Simona Miceska, Ursa Lampreht Tratar, Masa Bosnjak, Veronika Kloboves Prevodnik, Maja Cemazar, Lidija Kandolf Sekulovič, Gorazd Avguštin, Janja Ocvirk, Tanja Mesti
The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL. Biomedicines 11 (7) (2023)
Tanja Mesti, Cvetka Grašič Kuhar, Janja Ocvirk
Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors. Biomedicines 11 (3) (2023)